Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 660 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 660 shares of BioLife Solutions stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $16,803.60. Following the completion of the transaction, the chief financial officer now owns 120,960 shares in the company, valued at approximately $3,079,641.60. The trade was a 0.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Trading Up 5.7 %

Shares of BLFS traded up $1.41 during mid-day trading on Wednesday, reaching $26.25. 502,346 shares of the company were exchanged, compared to its average volume of 270,046. The business has a 50 day simple moving average of $26.67 and a two-hundred day simple moving average of $25.48. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a market capitalization of $1.22 billion, a PE ratio of -24.76 and a beta of 1.91. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter last year, the business earned ($0.21) EPS. On average, analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of BioLife Solutions

A number of institutional investors have recently bought and sold shares of the company. D.A. Davidson & CO. boosted its stake in BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after acquiring an additional 519 shares in the last quarter. Stifel Financial Corp boosted its position in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares in the last quarter. 1620 Investment Advisors Inc. boosted its position in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock valued at $117,000 after buying an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC bought a new stake in BioLife Solutions in the 4th quarter valued at about $26,000. Institutional investors own 93.24% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BLFS. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Benchmark reaffirmed a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Finally, TD Cowen increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.